Abstract 1256P
Background
Lung cancer is a cancer type with high morbidity and mortality in the word, the clinical prognosis of lung cancer patients is still poor, the main reason is the lack of effective early screening and diagnosis methods. Plasma circRNAs detected by droplet digital PCR may be ideal markers for liquid biopsy. However, droplet digital PCR detection of circRNAs in plasma for (early) diagnosis of lung adenocarcinoma has been rarely reported.
Methods
RNA sequencing analysis was performed in plasma from patients with early lung adenocarcinoma and healthy individuals. Droplet digital PCR was used to verify the differentially expressed genes. We evaluated their diagnostic efficacy and predict their biological functions of target genes.
Results
The copy numbers of circLZIC and circCEP350 in the plasma of lung adenocarcinoma patients were significantly higher than in plasma of healthy people (P<0.01), they are closely related to tumor size (P<0.05) and TNM stage (P<0.05),and the copy numbers in postoperative plasma of the same patient were significantly lower than those in preoperative plasma (P<0.05).ROC curve analysis showed that circLZIC (AUC=0.782) and circCEP350 (AUC=0.764) alone and in combination (AUC=0.863) had diagnostic value in lung adenocarcinoma, circLZIC (AUC=0.786) and circCEP350 (AUC=0.546) alone and in combination (AUC=0.803) had diagnostic value in early lung adenocarcinoma.Bioinformatics analysis revealed that circLZIC and circCEP350 had more binding sites with multiple microRNAs. Their target genes were enriched in several signaling pathways.
Conclusions
The copy numbers of circLZIC and circCEP350 were higher in plasma of lung adenocarcinoma patients than in plasma of healthy controls, significantly correlated with tumor size and TNM stage, and closely related to the occurrence and development of tumors. These circRNAs may serve as molecular markers for the diagnosis of lung adenocarcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14